TABLE 2.
Cancer risk in schizophrenia and Parkinson’s disease patients
| # | Study | Odds Ratio | 95% CI | Type | Cancer Type | Cohort (n) | Age | Sex | Diagnosis | Note |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Barak et al. (2005) | 0.58 | 0.48–0.69 | SIR | All types | 3226 | M/F | SCZ | ||
| 2 | Barak et al. (2005) | 0.6 | 0.39–0.90 | SIR | Breast | 1247 | F | SCZ | ||
| 3 | Becker et al. (2010) | 0.77 | 0.64–0.92 | IRR | All types | 2993 | M/F | PD | ||
| 4 | Becker et al. (2010) | 0.47 | 0.25–0.86 | IRR | Lung | 2993 | M/F | PD | ||
| 5 | Becker et al. (2010) | 0.33 | 0.18–0.61 | IRR | Lymphoma/leukemia | 2993 | M/F | PD | ||
| 6 | Becker et al. (2010) | 1.7 | 0.62–4.67 | IRR | Melanoma | 2993 | M/F | PD | ||
| 7 | Driver et al. (2007) | 0.85 | 0.59–1.22 | Adjusted RR | All types | 487 | M/F | PD | Prospective | |
| 8 | Driver et al. (2007) | 0.32 | 0.07–1.53 | Adjusted RR | Lung | 487 | M/F | PD | Prospective | |
| 9 | Driver et al. (2007) | 0.54 | 0.14–2.16 | Adjusted RR | Colorectal | 487 | M/F | PD | Prospective | |
| 10 | Driver et al. (2007) | 6.15 | 1.77–21.37 | Adjusted RR | Melanoma | 487 | M/F | PD | Prospective | |
| 11 | Jansson and Jankovic (1985) | ∼0.33 | Combined IR | All types | 406 | M/F | PD | |||
| 12 | Jespersen et al. (2016) | 0.73 | 0.63–0.83 | Adjusted OR | Prostate | 45,429 | M | PD | Case control | |
| 13 | Lichtermann et al. (2001) | 1.17 | 1.09–1.25 | SIR | All types | 26,996 | M/F | SCZ | ||
| 14 | 2.17 | 1.78–2.6 | SIR | Lung | 26,996 | M/F | SCZ | Not controlled for smoking | ||
| 15 | Wu et al. (2013) | 0.92 | 0.9–0.96 | SIR | All types | 102,202 | All | M/F | SCZ | Declines with age |
| 16 | Wu et al. (2013) | 1.97 | 1.85–2.33 | SIR | All types | 102,202 | 20–29 | M/F | SCZ | |
| 17 | Wu et al. (2013) | 0.68 | 0.65–0.78 | SIR | All types | 102,202 | 60–69 | M/F | SCZ | |
| 18 | Wu et al. (2013) | 0.36 | 0.34–0.45 | SIR | All types | 102,202 | >70 | M/F | SCZ | |
| 19 | Hamaue et al. (2000) | <1 | SIR | All types | 246 | M/F | PD | Retrospective, not significant (small sample size) | ||
| 20 | Moller et al. (1995) | 0.88 | 0.8–1.0 | Relative risk | All types | 7046 | M/F | PD | National cohort | |
| 21 | Moller et al. (1995) | 0.29 | 0.2–0.4 | Relative risk | Lung | 7046 | M/F | PD | ||
| 22 | Moller et al. (1995) | 1.96 | 1.1–3.2 | Relative risk | Melanoma | 7046 | M/F | PD | ||
| 23 | Moller et al. (1995) | 0.42 | 0.2–0.7 | Relative risk | Bladder | 7046 | M/F | PD | ||
| 24 | Munk-Jorgensen and Mortensen (1989) | 0.9 | IRR | All types | 6152 | All | M/F | SCZ | ||
| 25 | Munk-Jorgensen and Mortensen (1989) | 0.76 | IRR | All types | 2956 | All | M | SCZ | ||
| 26 | Munk-Jorgensen and Mortensen (1989) | 1.06 | IRR | All types | 3196 | All | F | SCZ | ||
| 27 | Munk-Jorgensen and Mortensen (1989) | 0.38 | IRR | Respiratory | 6152 | All | M/F | SCZ | ||
| 28 | Eaton et al. (1992) | 0.33 | 0.12–0.94 | IRR | Prostate | 38 | All | M | SCZ | Treated with high dose neuroleptics (e.g., chlorpromazine) |
| 29 | Mortensen (1994) | 0.79 | SIR | All types | 9156 | All | M/F | SCZ | With SCZ diagnosis | |
| 30 | Mortensen (1994) | 1.06 | SIR | All types | 5658 | M | SCZ | |||
| 31 | Mortensen (1994) | 0.68 | SIR | All types | 5658 | M | SCZ | Before SCZ diagnosis | ||
| 32 | Mortensen (1994) | 0.77 | SIR | All types | 3498 | F | SCZ | Before SCZ diagnosis | ||
| 33 | Mortensen (1994) | 0.86 | SIR | All types | 3498 | F | SCZ | |||
| 34 | Wang et al. (2015) | 2.16 | 1.55–2.99 | Adjusted OR | All types | 6211 | All | M/F | PD | Patients prescribed ergot-derived dopamine agonists |
SIR, Standardized Risk Ratio; IRR, Incident Rate Ratio; RR, Relative Risk; OR, Odds Ration.